Literature DB >> 21257740

Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets.

Grace L Chen1, Ji-Young Min, Elaine W Lamirande, Celia Santos, Hong Jin, George Kemble, Kanta Subbarao.   

Abstract

The role of seasonal influenza vaccination in pandemic influenza A H1N1 disease is important to address, because a large segment of the population is vaccinated annually. We administered 1 or 2 doses of pandemic H1N1 vaccine (CA/7 ca), a seasonal trivalent inactivated (s-TIV), or live attenuated influenza vaccine (s-LAIV) to mice and ferrets and subsequently challenged them with a pandemic H1N1 virus. In both species, CA/7 ca was immunogenic and conferred complete protection against challenge. s-TIV did not confer protection in either animal model, and s-LAIV did not confer any protection in ferrets. In mice, 2 doses of s-LAIV led to complete protection in the upper respiratory tract and partial protection in the lungs. Our data indicate that vaccination with the seasonal influenza vaccines did not confer complete protection in the lower respiratory tract in either animal model, whereas the CA/7 ca vaccine conferred complete protection in both animal models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21257740      PMCID: PMC3068036          DOI: 10.1093/infdis/jiq144

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-11-13       Impact factor: 17.586

2.  Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination.

Authors:  H Kelly; K Grant
Journal:  Euro Surveill       Date:  2009-08-06

3.  2009 pandemic influenza A (H1N1) virus infections - Chicago, Illinois, April-July 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-08-28       Impact factor: 17.586

4.  Epidemiological characteristics of pandemic influenza H1N1 2009 and seasonal influenza infection.

Authors:  Heath A Kelly; Kristina A Grant; Simon Williams; James Fielding; David Smith
Journal:  Med J Aust       Date:  2009-08-03       Impact factor: 7.738

5.  Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment.

Authors:  John Steel; Peter Staeheli; Samira Mubareka; Adolfo García-Sastre; Peter Palese; Anice C Lowen
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

6.  Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis.

Authors:  Santiago Echevarría-Zuno; Juan Manuel Mejía-Aranguré; Alvaro J Mar-Obeso; Concepción Grajales-Muñiz; Eduardo Robles-Pérez; Margot González-León; Manuel Carlos Ortega-Alvarez; Cesar Gonzalez-Bonilla; Ramón Alberto Rascón-Pacheco; Víctor Hugo Borja-Aburto
Journal:  Lancet       Date:  2009-11-11       Impact factor: 79.321

7.  Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population.

Authors:  Jason A Greenbaum; Maya F Kotturi; Yohan Kim; Carla Oseroff; Kerrie Vaughan; Nima Salimi; Randi Vita; Julia Ponomarenko; Richard H Scheuermann; Alessandro Sette; Bjoern Peters
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

8.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Authors:  Kathy Hancock; Vic Veguilla; Xiuhua Lu; Weimin Zhong; Eboneé N Butler; Hong Sun; Feng Liu; Libo Dong; Joshua R DeVos; Paul M Gargiullo; T Lynnette Brammer; Nancy J Cox; Terrence M Tumpey; Jacqueline M Katz
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

9.  Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus.

Authors:  Gary P Kobinger; Isabelle Meunier; Ami Patel; Stéphane Pillet; Jason Gren; Shane Stebner; Anders Leung; James L Neufeld; Darwyn Kobasa; Veronika von Messling
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

10.  Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City.

Authors:  Lourdes Garcia-Garcia; Jose Luis Valdespino-Gómez; Eduardo Lazcano-Ponce; Aida Jimenez-Corona; Anjarath Higuera-Iglesias; Pablo Cruz-Hervert; Bulmaro Cano-Arellano; Antonio Garcia-Anaya; Elizabeth Ferreira-Guerrero; Renata Baez-Saldaña; Leticia Ferreyra-Reyes; Samuel Ponce-de-León-Rosales; Celia Alpuche-Aranda; Mario Henry Rodriguez-López; Rogelio Perez-Padilla; Mauricio Hernandez-Avila
Journal:  BMJ       Date:  2009-10-06
View more
  22 in total

1.  Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus.

Authors:  Seema S Lakdawala; Elaine W Lamirande; Amorsolo L Suguitan; Weijia Wang; Celia P Santos; Leatrice Vogel; Yumiko Matsuoka; William G Lindsley; Hong Jin; Kanta Subbarao
Journal:  PLoS Pathog       Date:  2011-12-29       Impact factor: 6.823

2.  Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses.

Authors:  Yo Han Jang; Young Ho Byun; Yoon Jae Lee; Yun Ha Lee; Kwang-Hee Lee; Baik Lin Seong
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Sequencing, annotation, and characterization of the influenza ferret infectome.

Authors:  Alberto J León; David Banner; Luoling Xu; Longsi Ran; Zhiyu Peng; Kang Yi; Chao Chen; Fengping Xu; Jinrong Huang; Zhen Zhao; Zhen Lin; Stephen H S Huang; Yuan Fang; Alyson A Kelvin; Ted M Ross; Amber Farooqui; David J Kelvin
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

4.  Receptor specificity does not affect replication or virulence of the 2009 pandemic H1N1 influenza virus in mice and ferrets.

Authors:  Seema S Lakdawala; Angela R Shih; Akila Jayaraman; Elaine W Lamirande; Ian Moore; Myeisha Paskel; Heather Kenney; Ram Sasisekharan; Kanta Subbarao
Journal:  Virology       Date:  2013-09-10       Impact factor: 3.616

5.  Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates.

Authors:  Kobporn Boonnak; Myeisha Paskel; Yumiko Matsuoka; Leatrice Vogel; Kanta Subbarao
Journal:  Vaccine       Date:  2012-07-10       Impact factor: 3.641

6.  Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus.

Authors:  Christopher D O'Donnell; Amber Wright; Leatrice N Vogel; Chih-Jen Wei; Gary J Nabel; Kanta Subbarao
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

7.  Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

Authors:  Joseph N Brewoo; Tim D Powell; Jeremy C Jones; Nancy A Gundlach; Ginger R Young; Haiyan Chu; Subash C Das; Charalambos D Partidos; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2013-02-01       Impact factor: 3.641

Review 8.  Cross-protective immune responses elicited by live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

9.  All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.

Authors:  Hongjun Chen; Matthew Angel; Weizhong Li; Courtney Finch; Ana Silvia Gonzalez; Troy Sutton; Jefferson Santos; Daniel R Perez
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

10.  Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus.

Authors:  Christopher D O'Donnell; Amber Wright; Leatrice Vogel; Kobporn Boonnak; John J Treanor; Kanta Subbarao
Journal:  Clin Vaccine Immunol       Date:  2014-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.